The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 155 results:
Author Title Type [ Year(Asc)]
Filters: Keyword is Diabetes Mellitus, Type 2  [Clear All Filters]
2024
Karagiannis, T., Tsapas A., Bekiari E., Toulis K. A., & Nauck M. A. (2024).  A Methodological Framework for Meta-analysis and Clinical Interpretation of Subgroup Data: The Case of Major Adverse Cardiovascular Events With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes.. Diabetes Care. 47(2), 184-192.
2023
Georgianos, P. I., Eleftheriadis T., & Liakopoulos V. (2023).  Combination therapy with an SGLT-2 inhibitor and finerenone in DKD: Are we there yet?. Eur J Clin Invest. 53(2), e13864.
Malandris, K., Papandreou S., Avgerinos I., Karagiannis T., Paschos P., Michailidis T., et al. (2023).  Comparative efficacy of glucose-lowering drugs on liver steatosis as assessed by means of magnetic resonance imaging in patients with type 2 diabetes mellitus: systematic review and network meta-analysis.. Hormones (Athens). 22(4), 655-664.
Avgerinos, I., Karagiannis T., Matthews D. R., Tsapas A., & Bekiari E. (2023).  Effects of sodium-glucose co-transporter-2 inhibitors by background cardiovascular medications: A systematic review and meta-analysis.. Diabetes Obes Metab. 25(10), 3020-3029.
Karakousis, N. D., Biliou S., Pyrgioti E. E., Georgakopoulos P. N., Liakopoulos V., & Papanas N. (2023).  Frailty, sarcopenia and diabetic kidney disease: where do we stand?. Int Urol Nephrol. 55(5), 1173-1181.
Liakos, A., Karagiannis T., Avgerinos I., Malandris K., Tsapas A., & Bekiari E. (2023).  Management of type 2 diabetes in the new era.. Hormones (Athens). 22(4), 677-684.
Polyzos, S. A., Frühbeck G., & Kiortsis D. N. (2023).  Peptide Polyagonists for the Treatment of Nonalcoholic Fatty Liver Disease.. Curr Pharm Des. 29(41), 3263-3265.
Avgerinos, I., Karagiannis T., Liakos A., Tsapas A., & Bekiari E. (2023).  Racial, ethnic and sex disparities among participants in cardiovascular outcomes trials in type 2 diabetes: A systematic review and descriptive analysis.. Diabetes Obes Metab. 25(2), 618-622.
Karagiannis, T., Bekiari E., & Tsapas A. (2023).  Socioeconomic aspects of incretin-based therapy.. Diabetologia. 66(10), 1859-1868.
Georgianos, P. I., Vaios V., Eleftheriadis T., Papachristou E., & Liakopoulos V. (2023).  Therapeutic Advances in Diabetic Kidney Disease.. Int J Mol Sci. 24(3), 
2022
Karagiannis, T., Avgerinos I., Liakos A., Del Prato S., Matthews D. R., Tsapas A., et al. (2022).  Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.. Diabetologia. 65(8), 1251-1261.
Nikolaidou, B., Anyfanti P., Gavriilaki E., Lazaridis A., Triantafyllou A., Zarifis H., et al. (2022).  Non-dipping pattern in early-stage diabetes: association with glycemic profile and hemodynamic parameters.. J Hum Hypertens. 36(9), 805-810.
Avgerinos, I., Karagiannis T., Kakotrichi P., Michailidis T., Liakos A., Matthews D. R., et al. (2022).  Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis.. Diabetes Obes Metab. 24(1), 106-114.
2021
Tsapas, A., Karagiannis T., Avgerinos I., Matthews D. R., & Bekiari E. (2021).  Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes.. Ann Intern Med. 174(1), 141.
Tsapas, A., Karagiannis T., Kakotrichi P., Avgerinos I., Mantsiou C., Tousinas G., et al. (2021).  Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis.. Diabetes Obes Metab. 23(9), 2116-2124.
Papadopoulou, E., Theodorakopoulou M. P., Loutradis C., Tzanis G., Tzatzagou G., Kotsa K., et al. (2021).  Dapagliflozin Does Not Affect Short-Term Blood Pressure Variability in Patients With Type 2 Diabetes Mellitus.. Am J Hypertens. 34(4), 404-413.
Karagiannis, T., Tsapas A., Athanasiadou E., Avgerinos I., Liakos A., Matthews D. R., et al. (2021).  GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis.. Diabetes Res Clin Pract. 174, 108737.
Tsapas, A., Karagiannis T., Avgerinos I., Liakos A., & Bekiari E. (2021).  GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials.. Diabetes Res Clin Pract. 177, 108921.
Kyriakidou, A., Koufakis T., Goulis D. G., Vasilopoulos Y., Zebekakis P., & Kotsa K. (2021).  Pharmacogenetics of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide: A Step Towards Personalized Type 2 Diabetes Management.. Curr Pharm Des. 27(8), 1025-1034.
Anagnostis, P., Paparodis R. D., Bosdou J. K., Bothou C., Macut D., Goulis D. G., et al. (2021).  Risk of type 2 diabetes mellitus in polycystic ovary syndrome is associated with obesity: a meta-analysis of observational studies.. Endocrine. 74(2), 245-253.
Avgerinos, I., Papanastasiou G., Karagiannis T., Michailidis T., Liakos A., Mainou M., et al. (2021).  Ultra-rapid-acting insulins for adults with diabetes: A systematic review and meta-analysis.. Diabetes Obes Metab. 23(10), 2395-2401.
2020
Tsapas, A., Avgerinos I., Karagiannis T., Malandris K., Manolopoulos A., Andreadis P., et al. (2020).  Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.. Ann Intern Med. 173(4), 278-286.
Moralidis, E., Papanastasiou E., Didangelos T., Hilidis I., Siountas A., & Arsos G. (2020).  Determination of the glomerular filtration rate in patients with type 2 diabetes: An assessment of the agreement between Cr-EDTA plasma clearance and Tc-DTPA plasma clearance, Tc-DTPA renography and plasma creatinine prediction equation.. Diabetes Res Clin Pract. 161, 108079.
Mantsiou, C., Karagiannis T., Kakotrichi P., Malandris K., Avgerinos I., Liakos A., et al. (2020).  Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.. Diabetes Obes Metab. 22(10), 1857-1868.
Liakos, A., Tsapas A., & Bekiari E. (2020).  In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors.. Ann Intern Med. 173(12), JC70.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.